CD8A and neoplasm: In animal models, antibodies to the GITR have been shown to partially deplete Treg in vivo in the tumor microenvironment and to simultaneously provide co-stimulatory signals to CD4+ and CD8+ T effector cells resulting in inhibition of tumor growth (50).